Company / Operating Income
Dianthus Therapeutics, Inc. /DE/ Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$177.9M
FY2025
5-year range
-$177.9M / -$29.7M
FY2021-FY2025
Trend
-269.4%
vs FY2024
Sector context
#131 of 204
Health Care
What the data says
Operating Income changed -269% YoY in FY2025, a notable deviation from the 9-year average annual change of -73%.
Based on SEC 10-K filings.
-$178M in FY2025.
Declined from -$48M to -$178M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#131 of 204 in Health CareTop 64% of 204This company -$177.9M Sector average $107.8M
▼
-265.1% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 269.4% year-over-year.
- Ranks #131 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$177.9M | -269.4% |
| FY2024 | -$48.2M | +0.0% |
| FY2023 | -$48.2M | -62.2% |
| FY2022 | -$29.7M | +60.2% |
| FY2021 | -$74.7M | +5.1% |
| FY2020 | -$78.7M | +5.1% |
| FY2019 | -$83.0M | -38.4% |
| FY2018 | -$60.0M | -67.8% |
| FY2017 | -$35.7M | -285.5% |
| FY2016 | -$9.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026